A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

This trial is testing a targeted antibody drug called zanidatamab (ZW25) in patients with early-stage HER2-positive breast cancer — a type of breast cancer driven by a protein called HER2 — before surgery. **You may be eligible if...** - You are over 18 with HER2-positive breast cancer - Your tumor is between 1 cm and 3 cm and has not spread to lymph nodes or elsewhere - You have not had any previous treatment for this breast cancer - Your heart function is normal - You are willing to have surgery after the study treatment **You may NOT be eligible if...** - Your tumor is larger than 3 cm or has spread - You have already received treatment for this current breast cancer - You have significant heart disease (heart failure, recent heart attack, uncontrolled high blood pressure) - You have HIV, active hepatitis B or C - You are pregnant or breastfeeding - You have had a major surgery in the past 4 weeks - You have a history of severe allergic reactions to antibody drugs - You require high-dose steroids or immune-suppressing drugs Talk to your doctor to see if this trial is right for you.